Products
Eflornithine is commercially available as a cream in many countries and has been approved since 2003 (Vaniqa). Vaniqa was released in the United States in 2000 and in the EU in 2001.
Structure and properties
Eflornithine (C6H12F2N2O2, Mr = 182.2 g/mol) is a fluorinated and methylated derivative of the amino acid ornithine. It is present in the drug as eflornithine hydrochloride monohydrate.
Effects
Eflornithine (ATC D11AX16) slows hair growth. The effects are due to irreversible inhibition of the enzyme ornithine decarboxylase in the skin, which is involved in the synthesis of amines (putrescine). This reduces cell division, cell growth and cell differentiation in the hair follicle and delays hair growth. The effect usually occurs within 8 weeks of starting therapy. Eflornithine also has antiparasitic properties and is used for the treatment of African trypanosomiasis. This article refers to external administration.
Indications
For the treatment of hirsutism (abnormal hair growth) on the face in women.
Dosage
According to the professional information. The cream is applied thinly to the affected cleansed and dry skin areas twice a day, at least 8 hours apart, and massaged in thoroughly.
Contraindications
- Hypersensitivity
For complete precautions, see the drug label.
Interactions
No interactions with other drugs are known to date.
Adverse effects
Acne occurs as the most common possible adverse effect. In addition, other local skin reactions such as a stinging, burning, redness, tingling, and a rash may occur.